Why the study?
Given differing pharmacodynamic, pharmacogenomic, and safety-efficacy profiles among clopidogrel, prasugrel, and ticagrelor, the optimal selection of oral P2Y12 inhibitors remains an active area of investigation.
Comparison
Clopidogrel, prasugrel, and ticagrelor with or without aspirin
Design
Review
Key result
The selection of oral P2Y12 inhibitors should be individualized based on clinical, demographic, and genetic factors to balance ischemic and bleeding risks.
Authors
Loading...
Supports individualized P2Y12 selection in ASCVD practice; extends prior syntheses by emphasizing dynamic risk reassessment.
Systematic Review
Selection of oral P2Y12 inhibitors in ASCVD patients should be individualized based on clinical, demographic, and genetic factors, balancing ischemic and bleeding risks.
Galli et al. (2025) conducted a systematic review in Atherosclerotic cardiovascular disease. Oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) was evaluated. The selection of oral P2Y12 inhibitors should be individualized based on clinical, demographic, and genetic factors to balance ischemic and bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: